amikacin has been researched along with malondialdehyde in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, QJ; Chen, H; Qu, XH; Xiao, M; Xie, KJ | 1 |
| Dionyssiou-Asteriou, A; Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P | 1 |
| Dionyssiou-Asteriou, A; Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Plachouras, D; Raftogiannis, M; Skiathitis, S | 1 |
| Campbell, KC; Hughes, LF; Klemens, JJ; Meech, RP; Somani, S | 1 |
| Acet, A; Cigremis, Y; Ozer, MK; Parlakpinar, H; Sahna, E; Vardi, N | 1 |
| Acet, A; Koc, M; Ozer, MK; Parlakpinar, H; Polat, A; Turkoz, Y; Vardi, N | 1 |
| Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kousoulas, V; Koutoukas, P; Panagou, C; Perrea, D; Sabracos, L | 1 |
| Adamis, T; Baziaka, F; Giamarellos-Bourboulis, E; Giamarellou, H; Karayannacos, P; Koutoukas, P; Plachouras, D; Raftogiannis, M; Sabracos, L; Tsaganos, T | 1 |
| Adamis, T; Antonopoulou, A; Giamarellos-Bourboulis, EJ; Giamarellou, H; Koutoukas, P; Panagou, C; Raftogiannis, M; Tsaganos, T; Tziortzioti, V | 1 |
| Chaudhary, M; Dwivedi, VK; Soni, A | 1 |
| Asci, H; Bayram, D; Cicek, E; Oncu, M; Ozer, MK; Savran, M; Yesilot, S | 1 |
| Chaudhary, M; Dwivedi, VK; Shrivastava, SM; Singh, CP; Soni, A | 1 |
| Beytur, A; Cinar, K; Dogan, Z; Ekinci, N; Ekincioglu, Z; Kose, E; Soysal, H; Turkoz, Y; Vardi, N | 1 |
| Asci, H; Bayram, D; Candan, IA; Cankara, FN; Ilhan, I; Saygin, M; Yesilot, S | 1 |
| Altuntas, I; Cetin, H; Kara, A; Kaya, S; Metin Ciris, I; Oktem, F | 1 |
| Alp, HH; Ari, E; Basbugan, Y; Bayram, I; Bektas, H; Bulut, G; Erten, R | 1 |
| Armagan, I; Bilgic, S; Ozer, MK; Savran, M | 1 |
17 other study(ies) available for amikacin and malondialdehyde
| Article | Year |
|---|---|
[Intervention effects of oral active AdipoRon on liver oxidative stress in type 2 diabetic mice].
Topics: Animals; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Liver; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Oxidative Stress; Piperidines; Receptors, Adiponectin; Superoxide Dismutase | 2017 |
In vitro activity of polyunsaturated fatty acids on Pseudomonas aeruginosa: relationship to lipid peroxidation.
Topics: Amikacin; Ampicillin Resistance; Anti-Bacterial Agents; Arachidonic Acid; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Colony Count, Microbial; Drug Resistance, Microbial; Drug Resistance, Multiple; Fatty Acids, Unsaturated; gamma-Linolenic Acid; Gentamicins; Imipenem; Lipid Peroxidation; Malondialdehyde; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas aeruginosa; Species Specificity; Thienamycins; Ticarcillin; Tobramycin; Vitamin E | 1998 |
Ex vivo synergy of arachidonate-enriched serum with ceftazidime and amikacin on multidrug-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Arachidonic Acid; Ceftazidime; Cephalosporins; Colony Count, Microbial; Culture Media; Drug Resistance, Multiple, Bacterial; Drug Synergism; Lipid Peroxides; Male; Malondialdehyde; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Rabbits; Thiobarbituric Acid Reactive Substances; Time Factors | 2003 |
Antioxidant enzyme levels inversely covary with hearing loss after amikacin treatment.
Topics: Amikacin; Analysis of Variance; Animals; Anti-Bacterial Agents; Antioxidants; Case-Control Studies; Catalase; Cochlea; Evoked Potentials, Auditory, Brain Stem; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Guinea Pigs; Hearing Loss; Injections, Subcutaneous; Lipid Peroxidation; Malondialdehyde; Superoxide Dismutase | 2003 |
Amikacin-induced acute renal injury in rats: protective role of melatonin.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Blood Urea Nitrogen; Female; Glutathione; Kidney; Malondialdehyde; Melatonin; Pineal Gland; Rats; Rats, Wistar | 2003 |
Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats.
Topics: Amikacin; Analysis of Variance; Animals; Biopsy, Needle; Disease Models, Animal; Drug Interactions; Female; Guanidines; Immunohistochemistry; Kidney Diseases; Kidney Function Tests; Lipid Peroxidation; Malondialdehyde; Probability; Protective Agents; Random Allocation; Rats; Rats, Wistar; Sensitivity and Specificity | 2004 |
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Inflammation; Lipopolysaccharides; Malondialdehyde; Pyelonephritis; Rabbits; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha | 2005 |
Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Caspase 3; Caspases; Clarithromycin; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Immunologic Factors; Male; Malondialdehyde; Pulmonary Edema; Pyelonephritis; Rabbits; Sepsis; Tumor Necrosis Factor-alpha | 2005 |
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Immunologic Factors; Kidney; Lipopolysaccharides; Liver; Lung; Male; Malondialdehyde; Monocytes; Pseudomonas aeruginosa; Pseudomonas Infections; Pyelonephritis; Rabbits; Spleen; Tumor Necrosis Factor-alpha | 2006 |
Fixed dose combination of cefepime plus amikacin prevent oxidative stress in liver of Mus musculus mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Catalase; Cefepime; Cephalosporins; Drug Combinations; Lipid Peroxidation; Liver; Malondialdehyde; Mice; Oxidative Stress; Superoxide Dismutase | 2008 |
Effects of pentoxifylline on amikacin-induced nephrotoxicity in rats.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Blood Urea Nitrogen; Creatinine; Free Radical Scavengers; Kidney; Kidney Diseases; Male; Malondialdehyde; Pentoxifylline; Rats; Rats, Wistar | 2009 |
Fixed-dose combination of cefepime plus amikacin (potentox) inhibits pneumonia infection.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Catalase; Cefepime; Cephalosporins; Drug Therapy, Combination; Klebsiella Infections; Klebsiella pneumoniae; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Pneumonia, Bacterial; Rats; Rats, Wistar; Superoxide Dismutase | 2009 |
The effects of montelukast against amikacin-induced acute renal damage.
Topics: Acetates; Acute Disease; Amikacin; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Blood Urea Nitrogen; Creatinine; Cyclopropanes; Cytoprotection; Disease Models, Animal; Female; Glutathione; Immunohistochemistry; Interleukin-1beta; Kidney; Kidney Diseases; Malondialdehyde; Peroxidase; Quinolines; Rats; Rats, Wistar; Sulfides; Tumor Necrosis Factor-alpha | 2012 |
The impact of alpha-lipoic acid on amikacin-induced nephrotoxicity.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Female; Kidney; Kidney Function Tests; Malondialdehyde; Rats; Rats, Wistar; Renal Insufficiency; Thioctic Acid; Treatment Outcome | 2015 |
Amikacin induced renal damage and the role of the antioxidants on neonatal rats.
Topics: Amikacin; Animals; Animals, Newborn; Anti-Bacterial Agents; Antioxidants; Disease Models, Animal; Erythropoietin; Kidney Diseases; Kidney Function Tests; Malondialdehyde; Nitric Oxide; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Treatment Outcome; Vitamin E | 2016 |
Paricalcitol may improve oxidative DNA damage on experimental amikacin-induced nephrotoxicity model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Amikacin; Animals; Anti-Bacterial Agents; Bone Density Conservation Agents; Deoxyguanosine; Disease Models, Animal; DNA Damage; Ergocalciferols; Kidney; Kidney Diseases; Kidney Function Tests; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2016 |
Thymoquinone protection from amikacin induced renal injury in rats.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Antioxidants; Benzoquinones; Creatinine; Kidney; Kidney Diseases; Male; Malondialdehyde; Oxidative Stress; Rats, Sprague-Dawley | 2020 |